Brunilda Shtylla's Insider Trades & SAST Disclosures
Brunilda Shtylla's most recent trade in Sutro Biopharma Inc was a trade of 15,428 Common Stock done at an average price of $4.7 . Disclosure was reported to the exchange on Aug. 28, 2023.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Brunilda Shtylla.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sutro Biopharma Inc | Brunilda Shtylla | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 4.71 per share. | 28 Aug 2023 | 15,428 | 0 (0%) | 0% | 4.7 | 72,595 | Common Stock |
| Sutro Biopharma Inc | Brunilda Shtylla | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 4.59 per share. | 25 Aug 2023 | 11,613 | 12,928 (0%) | 0% | 4.6 | 53,282 | Common Stock |
| Sutro Biopharma Inc | Brunilda Shtylla | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy Common Stock) | |
| Sutro Biopharma Inc | Brunilda Shtylla | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 27,500 | 27,500 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Brunilda Shtylla | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 6,750 | 24,702 (0%) | 0% | - | Common Stock | |
| Sutro Biopharma Inc | Brunilda Shtylla | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 6,750 | 20,250 | - | - | Restricted Stock Unit (RSU) | |
| Sutro Biopharma Inc | Brunilda Shtylla | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.79 per share. | 03 Mar 2023 | 4,536 | 25,541 (0%) | 0% | 5.8 | 26,263 | Common Stock |
| Sutro Biopharma Inc | Brunilda Shtylla | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 4,375 | 29,077 (0%) | 0% | - | Common Stock | |
| Sutro Biopharma Inc | Brunilda Shtylla | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 4,375 | 8,750 | - | - | Restricted Stock Unit (RSU) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges